T1	Participants 79 142	nondiabetic patients with stage I or II chronic kidney disease.
T2	Participants 736 848	Thirty nondiabetic stage I or II CKD patients who had already been treated with angiotensin II receptor blockers
T3	Participants 1004 1012	Patients
T4	Participants 1040 1049	2 groups;
T5	Participants 1805 1842	nondiabetic hypertensive CKD patients
